Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT04840563

Surface Refractive Index Shift of Kalifilcon A Compared With Dailies Total1 and Precision1 Lenses

Conditions: Contact Lens Wear

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Phase: NA
Enrollment: 10
Sponsor: Bausch & Lomb Incorporated

Location: Bausch & Lomb Incorporated Rochester New York

Summary

This was a single-site, bilateral, repeated-measures insertion study in habitual soft contact lens wearers. Ten participants were enrolled. All participants attended a Screening/Dispensing Visit at which informed consent was obtained and eligibility was assessed. Eligible participants then wore each of three commercially available daily disposable soft contact lens types - kalifilcon A (Bausch + Lomb), Dailies Total1 (delefilcon A, Alcon) and Precision1 (verofilcon A, Alcon), all -3.00 D - bilaterally for wear times of 0.5, 1, 3, 5 and 10 minutes over a total of 6 study visits. A new lens pair was inserted for each wear time, with a 3-5 minute washout period between lens pairs. Immediately following removal, the right-eye lens was measured for surface refractive index on a Metricon M-2010 Prism Coupler.

Eligibility Criteria

Inclusion Criteria: 1. Be 18 years or older and have full legal capacity to volunteer. 2. Have physiologically normal anterior segments not exhibiting clinically significant biomicroscopy findings. 3. Have no active ocular disease or allergic conjunctivitis. 4. Not be using any topical ocular medications. 5. Be willing and able to follow instructions. 6. Have signed a statement of informed consent. Exclusion Criteria: 1. Participating in a conflicting study in the opinion of the Investigator. 2. Considered by the Investigator to not be a suitable candidate for participation.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04840563). StuddyBuddy aggregates publicly available trial information.